Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer

Journal of Clinical Oncology

Volumn 19, Issue 22, 2001, Pages 4216-4223

  Perez, E A ^a   Vogel, C L ^a   Irwin, D H ^a   Kirshner, J J ^a   Patel, R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME; VISCERA;

EID: 0035890811     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.22.4216     Document Type: Article

References (25)

1. Cancer statistics, 2001
2. Treatment of metastatic breast cancer
3. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over
4. Initial paclitaxel improves outcome compared with CMVP combination chemotherapy as frontline therapy in untreated metastatic breast cancer
5. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-26
6. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342
7. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
8. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial
9. Paclitaxel in metastatic breast cancer: A trial of two doses by 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines
10. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
11. Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response
12. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer
13. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
14. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
15. Phase II study to evaluate the efficacy of weekly paclitaxel (WP) in patients with metastatic breast cancer (MBC) who have failed prior anthracycline (A) +/- taxane (T) therapy
16. Phase II study of weekly paclitaxel (P) treatment in recurrent breast cancer after high-dose chemotherapy (HDC)
17. A promising second line treatment with weekly Taxol (T) in anthracycline recurrent, advanced breast cancer (ABC) patients (PTS)
18. Reinduction of response with weekly taxol (T) in advanced breast cancer (ABC)
19. Long-term weekly paclitaxel (P) in metastatic breast cancer (MBC): A phase II trial in pretreated patients (pts)
20. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer
21. Nonparametric estimation from incomplete observations
22. Reliability and validity of the functional assessment of cancer therapy breast quality-of-life instrument
23. Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor
24. Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer